Yoon Yeo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2157865/publications.pdf

Version: 2024-02-01

117	8,905	49	92
papers	citations	h-index	g-index
119	119	119	13572
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Local immunotherapy of cancer and metastasis. , 2022, , 483-528.		1
2	Development of hot-melt extruded drug/polymer matrices for sustained delivery of meloxicam. Journal of Controlled Release, 2022, 342, 189-200.	4.8	11
3	Meta-Analysis of Drug Delivery Approaches for Treating Intracellular Infections. Pharmaceutical Research, 2022, 39, 1085-1114.	1.7	5
4	Nucleic acid and oligonucleotide delivery for activating innate immunity in cancer immunotherapy. Journal of Controlled Release, 2022, 345, 586-600.	4.8	12
5	A single local delivery of paclitaxel and nucleic acids via an immunoactive polymer eliminates tumors and induces antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119 , .	3.3	10
6	Engineering microenvironment of biodegradable polyester systems for drug stability and release control. Therapeutic Delivery, 2021, 12, 37-54.	1.2	9
7	Local drug delivery systems for inflammatory diseases: Status quo, challenges, and opportunities. Journal of Controlled Release, 2021, 330, 438-460.	4.8	28
8	Nanosac, a Noncationic and Soft Polyphenol Nanocapsule, Enables Systemic Delivery of siRNA to Solid Tumors. ACS Nano, 2021, 15, 4576-4593.	7.3	39
9	Pharmacokinetic aspects of the clinically used proteasome inhibitor drugs and efforts toward nanoparticulate delivery systems. Journal of Pharmaceutical Investigation, 2021, 51, 483.	2.7	3
10	Nanocapsules modify membrane interaction of polymyxin B to enable safe systemic therapy of Gram-negative sepsis. Science Advances, 2021, 7, .	4.7	20
11	Incident Type 2 Diabetes Risk of Selective Estrogen Receptor Modulators in Female Patients with Breast Cancer. Pharmaceuticals, 2021, 14, 925.	1.7	7
12	Antibacterial nanotruffles for treatment of intracellular bacterial infection. Biomaterials, 2020, 262, 120344.	5.7	33
13	Bioresorbable, Miniaturized Porous Silicon Needles on a Flexible Water-Soluble Backing for Unobtrusive, Sustained Delivery of Chemotherapy. ACS Nano, 2020, 14, 7227-7236.	7.3	50
14	Topical application of zwitterionic chitosan suppresses neutrophil-mediated acute skin inflammation. International Journal of Biological Macromolecules, 2020, 158, 1184-1193.	3.6	14
15	Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model. Journal of Pharmaceutical Sciences, 2020, 109, 1615-1622.	1.6	3
16	Sustained Delivery of Carfilzomib by Tannic Acid-Based Nanocapsules Helps Develop Antitumor Immunity. Nano Letters, 2019, 19, 8333-8341.	4.5	51
17	Camouflaging Nanoparticles for Ratiometric Delivery of Therapeutic Combinations. Nano Letters, 2019, 19, 1479-1487.	4.5	24
18	In-vitro and in-vivo difference in gene delivery by lithocholic acid-polyethyleneimine conjugate. Biomaterials, 2019, 217, 119296.	5.7	37

#	Article	IF	Citations
19	Development of Liposomal Gemcitabine with High Drug Loading Capacity. Molecular Pharmaceutics, 2019, 16, 2858-2871.	2.3	44
20	Magnetophoretic Delivery of a Tumor-Priming Agent for Chemotherapy of Metastatic Murine Breast Cancer. Molecular Pharmaceutics, 2019, 16, 1864-1873.	2.3	9
21	Surface Modification of Polymeric Nanoparticles with M2pep Peptide for Drug Delivery to Tumor-Associated Macrophages. Pharmaceutical Research, 2019, 36, 65.	1.7	50
22	Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation. Journal of Controlled Release, 2019, 302, 148-159.	4.8	41
23	A Comparative In Vivo Study of Albuminâ€Coated Paclitaxel Nanocrystals and Abraxane. Small, 2018, 14, e1703670.	5.2	47
24	Enhancing Docetaxel Delivery to Multidrug-Resistant Cancer Cells with Albumin-Coated Nanocrystals. Molecular Pharmaceutics, 2018, 15, 871-881.	2.3	25
25	Radiation-enhanced delivery of plasmid DNA to tumors utilizing a novel PEI polyplex. Cancer Gene Therapy, 2018, 25, 196-206.	2.2	13
26	Recent advances in nanomedicine for sepsis treatment. Therapeutic Delivery, 2018, 9, 435-450.	1.2	23
27	Mixed Liposome Approach for Ratiometric and Sequential Delivery of Paclitaxel and Gemcitabine. AAPS PharmSciTech, 2018, 19, 693-699.	1.5	13
28	Quinic Acid onjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins. Small, 2018, 14, e1803601.	5.2	25
29	Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors. Biomaterials, 2018, 180, 206-224.	5.7	110
30	Quantitative Assessment of Nanoparticle Biodistribution by Fluorescence Imaging, Revisited. ACS Nano, 2018, 12, 6458-6468.	7.3	123
31	Development of Surface-Variable Polymeric Nanoparticles for Drug Delivery to Tumors. Molecular Pharmaceutics, 2017, 14, 1538-1547.	2.3	20
32	Albumin-coated nanocrystals for carrier-free delivery of paclitaxel. Journal of Controlled Release, 2017, 263, 90-101.	4.8	75
33	Small molecule delivery to solid tumors with chitosan-coated PLGA particles: A lesson learned from comparative imaging. Journal of Controlled Release, 2017, 268, 407-415.	4.8	24
34	Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine–Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth. ACS Nano, 2017, 11, 10135-10146.	7.3	84
35	Particle engineering for intracellular delivery of vancomycin to methicillin-resistant Staphylococcus aureus (MRSA)-infected macrophages. Journal of Controlled Release, 2017, 267, 133-143.	4.8	56
36	Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy. Expert Opinion on Drug Delivery, 2017, 14, 427-446.	2.4	21

#	Article	IF	CITATIONS
37	Polyethylenimine-Dermatan Sulfate Complex, a Bioactive Biomaterial with Unique Toxicity to CD146-Positive Cancer Cells. ACS Biomaterials Science and Engineering, 2017, 3, 990-999.	2.6	6
38	Succinylated Chitosan Derivative Has Local Protective Effects on Intestinal Inflammation. ACS Biomaterials Science and Engineering, 2017, 3, 1853-1860.	2.6	21
39	Zwitterionic chitosan for the systemic treatment of sepsis. Scientific Reports, 2016, 6, 29739.	1.6	11
40	Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals. Journal of Controlled Release, 2016, 235, 91-98.	4.8	42
41	Tannic Acid-Mediated Surface Functionalization of Polymeric Nanoparticles. ACS Biomaterials Science and Engineering, 2016, 2, 2294-2303.	2.6	104
42	Polymer–iron oxide composite nanoparticles for EPR-independent drug delivery. Biomaterials, 2016, 101, 285-295.	5.7	78
43	Drug delivery to macrophages: Challenges and opportunities. Journal of Controlled Release, 2016, 240, 202-211.	4.8	96
44	Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines. Advanced Drug Delivery Reviews, 2016, 104, 93-109.	6.6	77
45	Effects of Inhalable Microparticles of Seonpyejeongcheon-Tang in an Asthma Mouse Model - Effects of Microparticles of SJT Journal of Pharmacopuncture, 2016, 19, 303-311.	0.4	5
46	Release Kinetics Study of Poorly Water-Soluble Drugs from Nanoparticles: Are We Doing It Right?. Molecular Pharmaceutics, 2015, 12, 997-1003.	2.3	178
47	Low molecular weight chitosan-coated polymeric nanoparticles for sustained and pH-sensitive delivery of paclitaxel. Journal of Drug Targeting, 2015, 23, 725-735.	2.1	51
48	Photo-crosslinkable chitosan hydrogel as a bioadhesive for esophageal stents. Macromolecular Research, 2015, 23, 882-884.	1.0	2
49	Drug Carriers: Not an Innocent Delivery Man. AAPS Journal, 2015, 17, 1096-1104.	2.2	10
50	Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer. Biomaterials, 2015, 37, 312-319.	5.7	74
51	Controlled drug release from pharmaceutical nanocarriers. Chemical Engineering Science, 2015, 125, 75-84.	1.9	359
52	Reliability and validity of Leicester Cough Questionnaire Korean version. Chronic Respiratory Disease, 2014, 11, 147-152.	1.0	18
53	Extracellular stability of nanoparticulate drug carriers. Archives of Pharmacal Research, 2014, 37, 16-23.	2.7	21
54	Polydopamine-Based Simple and Versatile Surface Modification of Polymeric Nano Drug Carriers. ACS Nano, 2014, 8, 3347-3356.	7.3	363

#	Article	IF	CITATIONS
55	Stabilization of a hyaluronate-associated gene delivery system using calcium ions. Biomaterials Science, 2014, 2, 936-942.	2.6	6
56	Extracellularly activatable nanocarriers for drug delivery to tumors. Expert Opinion on Drug Delivery, 2014, 11, 1601-1618.	2.4	33
57	Effects of inhalable microparticle of flower of Lonicera japonica in a mouse model of COPD. Journal of Ethnopharmacology, 2014, 151, 123-130.	2.0	18
58	Prevention of peritoneal adhesions using polymeric rheological blends. Acta Biomaterialia, 2014, 10, 1187-1193.	4.1	19
59	A DNA prime-protein boost vaccination strategy targeting turkey coronavirus spike protein fragment containing neutralizing epitope against infectious challenge. Veterinary Immunology and Immunopathology, 2013, 152, 359-369.	0.5	12
60	Nanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies. Molecular Pharmaceutics, 2013, 10, 2093-2110.	2.3	274
61	Zwitterionic Chitosan–Polyamidoamine Dendrimer Complex Nanoparticles as a pH-Sensitive Drug Carrier. Molecular Pharmaceutics, 2013, 10, 1695-1704.	2.3	44
62	Polydopamine-Based Surface Modification for the Development of Peritumorally Activatable Nanoparticles. Pharmaceutical Research, 2013, 30, 1956-1967.	1.7	66
63	Development of Quinic Acid-Conjugated Nanoparticles as a Drug Carrier to Solid Tumors. Biomacromolecules, 2013, 14, 2389-2395.	2.6	23
64	Effects of Inhalable Microparticles of on Chronic Obstructive Pulmonary Disease in a Mouse Model. Journal of Korean Medicine, 2013, 34, 54-68.	0.1	6
65	Application of polysaccharides for surface modification of nanomedicines. Therapeutic Delivery, 2012, 3, 1447-1456.	1.2	66
66	Nanocrystals for the parenteral delivery of poorly water-soluble drugs. Current Opinion in Solid State and Materials Science, 2012, 16, 295-301.	5.6	100
67	Beyond the imaging: Limitations of cellular uptake study in the evaluation of nanoparticles. Journal of Controlled Release, 2012, 164, 170-176.	4.8	35
68	Cancer targeting strategies in nanomedicine: Design and application of chitosan nanoparticles. Current Opinion in Solid State and Materials Science, 2012, 16, 333-342.	5.6	42
69	Zwitterionic Chitosan Derivative, a New Biocompatible Pharmaceutical Excipient, Prevents Endotoxin-Mediated Cytokine Release. PLoS ONE, 2012, 7, e30899.	1.1	48
70	Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2012, 4, 219-233.	3.3	393
71	Low Molecular-Weight Chitosan as a pH-Sensitive Stealth Coating for Tumor-Specific Drug Delivery. Molecular Pharmaceutics, 2012, 9, 1262-1270.	2.3	131
72	Semi-interpenetrating network of polyethylene glycol and photocrosslinkable chitosan as an in-situ-forming nerve adhesive. Acta Biomaterialia, 2012, 8, 1849-1858.	4.1	42

#	Article	lF	CITATIONS
73	Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. Journal of Controlled Release, 2012, 158, 386-392.	4.8	123
74	Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease. Expert Opinion on Drug Delivery, 2011, 8, 451-466.	2.4	26
75	Effects of So-cheong-ryong-tang and Yeon-gyo-pae-dok-san on the common cold: Randomized, double blind, placebo controlled trial. Journal of Ethnopharmacology, 2011, 133, 642-646.	2.0	23
76	A strategy to deliver genes to cystic fibrosis lungs: A battle with environment. Journal of Controlled Release, 2011, 155, 289-295.	4.8	30
77	Rapidly Photo-Cross-Linkable Chitosan Hydrogel for Peripheral Neurosurgeries. Biomacromolecules, 2011, 12, 57-65.	2.6	76
78	Intratumoral Drug Delivery with Nanoparticulate Carriers. Pharmaceutical Research, 2011, 28, 1819-1830.	1.7	145
79	Mannitolâ€Guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model. Biotechnology and Bioengineering, 2011, 108, 1441-1449.	1.7	59
80	Development of inhalable dry powder formulation of basic fibroblast growth factor. International Journal of Pharmaceutics, 2010, 385, 66-72.	2.6	21
81	Drug Delivery Systems for Intraperitoneal Therapy. Pharmaceutical Research, 2010, 27, 735-738.	1.7	94
82	Inhalable Antibiotic Delivery Using a Dry Powder Co-delivering Recombinant Deoxyribonuclease and Ciprofloxacin for Treatment of Cystic Fibrosis. Pharmaceutical Research, 2010, 27, 151-160.	1.7	49
83	Photocrosslinkable chitosan modified with angiopoietinâ€1 peptide, QHREDGS, promotes survival of neonatal rat heart cells. Journal of Biomedical Materials Research - Part A, 2010, 95A, 105-117.	2.1	40
84	Battling with environments: drug delivery to target tissues with particles and functional biomaterials. Therapeutic Delivery, 2010, 1, 757-761.	1.2	4
85	Differential Effects of Insufflated, Subcutaneous, and Intravenous Growth Hormone on Bone Growth, Cognitive Function, and NMDA Receptor Subunit Expression. Endocrinology, 2010, 151, 4418-4427.	1.4	11
86	Zwitterionic Chitosan Derivatives for pH-Sensitive Stealth Coating. Biomacromolecules, 2010, 11, 2352-2358.	2.6	97
87	Nanoparticles for tumor-specific intracellular drug delivery. , 2009, 2009, 2403-5.		2
88	Gene delivery through the use of a hyaluronate-associated intracellularly degradable crosslinked polyethyleneimine. Biomaterials, 2009, 30, 5834-5843.	5.7	86
89	Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials, 2009, 30, 1947-1953.	5.7	235
90	Intracellular Drug Delivery by Poly(lactic- <i>co</i> -glycolic acid) Nanoparticles, Revisited. Molecular Pharmaceutics, 2009, 6, 190-201.	2.3	210

#	Article	IF	Citations
91	Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery. Molecular Pharmaceutics, 2009, 6, 1041-1051.	2.3	405
92	A Photo-Crosslinkable Chitosan Hydrogel for Peripheral Nerve Anastomosis., 2009,,.		1
93	Microenvironment-Controlled Encapsulation (MiCE) Process: Effects of PLGA Concentration, Flow Rate, and Collection Method on Microcapsule Size and Morphology. Pharmaceutical Research, 2008, 25, 5-15.	1.7	12
94	Microparticles for Inhalational Delivery of Antipseudomonal Antibiotics. AAPS Journal, 2008, 10, 254-60.	2.2	31
95	Polymers in the prevention of peritoneal adhesions. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 57-66.	2.0	108
96	Antifungal hydrogels. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12994-12998.	3.3	101
97	In Situ Cross-linkable Hyaluronan Hydrogels Containing Polymeric Nanoparticles for Preventing Postsurgical Adhesions. Annals of Surgery, 2007, 245, 819-824.	2.1	95
98	Photocrosslinkable hydrogel for myocyte cell culture and injection. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2007, 81B, 312-322.	1.6	113
99	The prevention of peritoneal adhesions by in situ cross-linking hydrogels of hyaluronic acid and cellulose derivatives. Biomaterials, 2007, 28, 975-983.	5.7	239
100	Peritoneal adhesion prevention with an in situ cross-linkable hyaluronan gel containing tissue-type plasminogen activator in a rabbit repeated-injury model. Biomaterials, 2007, 28, 3704-3713.	5.7	47
101	Dextran-based in situ cross-linked injectable hydrogels to prevent peritoneal adhesions. Biomaterials, 2007, 28, 3418-3426.	5.7	126
102	Prevention of peritoneal adhesions with an in situ cross-linkable hyaluronan hydrogel delivering budesonide. Journal of Controlled Release, 2007, 120, 178-185.	4.8	62
103	Anti-inflammatory function of an in situ cross-linkable conjugate hydrogel of hyaluronic acid and dexamethasone. Biomaterials, 2007, 28, 1778-1786.	5.7	115
104	Reservoir-Type Microcapsules Prepared by the Solvent Exchange Method:  Effect of Formulation Parameters on Microencapsulation of Lysozyme. Molecular Pharmaceutics, 2006, 3, 135-143.	2.3	23
105	Hyaluronic Acid-Based Microgels and Microgel Networks for Vocal Fold Regeneration. Biomacromolecules, 2006, 7, 3336-3344.	2.6	221
106	Micromolding of photocrosslinkable chitosan hydrogel for spheroid microarray and co-cultures. Biomaterials, 2006, 27, 5259-5267.	5.7	309
107	A photolithographic method to create cellular micropatterns. Biomaterials, 2006, 27, 4755-4764.	5 .7	118
108	In situ cross-linkable hyaluronic acid hydrogels prevent post-operative abdominal adhesions in a rabbit model. Biomaterials, 2006, 27, 4698-4705.	5.7	205

YOON YEO

#	Article	IF	CITATIONS
109	A New Microencapsulation Technique Based on the Solvent Exchange Method. ACS Symposium Series, 2006, , 242-252.	0.5	2
110	Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. Journal of Biomedical Materials Research - Part A, 2006, 77A, 351-361.	2.1	182
111	Peritoneal application of chitosan and UVâ€crossâ€linkable chitosan. Journal of Biomedical Materials Research - Part A, 2006, 78A, 668-675.	2.1	60
112	Complex Coacervates for Thermally Sensitive Controlled Release of Flavor Compounds. Journal of Agricultural and Food Chemistry, 2005, 53, 7518-7525.	2.4	184
113	A new microencapsulation method using an ultrasonic atomizer based on interfacial solvent exchange. Journal of Controlled Release, 2004, 100, 379-388.	4.8	65
114	Solvent Exchange Method: A Novel Microencapsulation Technique Using Dual Microdispensers. Pharmaceutical Research, 2004, 21, 1419-1427.	1.7	42
115	Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Archives of Pharmacal Research, 2004, 27, 1-12.	2.7	460
116	A new process for making reservoir-type microcapsules using ink-jet technology and interfacial phase separation. Journal of Controlled Release, 2003, 93, 161-173.	4.8	69
117	Microencapsulation methods for delivery of protein drugs. Biotechnology and Bioprocess Engineering, 2001, 6, 213-230.	1.4	140